The mannan-induced psoriatic arthritis mouse model is a well-established preclinical platform for studying psoriatic arthritis (PsA) and evaluating therapeutic candidates. A single intraperitoneal injection of mannan induces both inflammatory arthritis and psoriasis-like skin lesions in susceptible mouse strains, recapitulating key clinical and immunological features of human PsA. The model is characterized by joint swelling, erythema, epidermal hyperplasia, and immune cell infiltration, and is driven by innate immune activation with subsequent IL-17A-mediated inflammatory responses.
Download
This brochure by Ace Therapeutics introduces the mannan-induced psoriatic arthritis mouse model, highlighting the disease phenotype, core immunological mechanisms, and key evaluation endpoints.
- Disease phenotype: Simultaneous development of arthritis and psoriasis-like skin lesions.
- Clinically relevant pathology: Joint swelling, erythema, epidermal hyperplasia, and immune cell infiltration.
- Immune-driven mechanism: Innate immunity activation with IL-17A-mediated inflammatory responses.
- Reliable and reproducible: Consistent disease progression in DBA/1 and C57BL/6 mouse strains.
- Clinical endpoints: Psoriasis score, arthritis score, PASI score, body weight
- Histopathology: Skin and joint tissue analysis (inflammation, hyperkeratosis)
- Molecular analysis: Cytokine profiling (IL-6, IL-17A, TNF-α)
- Systemic indicators: Spleen index and inflammatory biomarkers
- Evaluation of anti-psoriatic and anti-arthritic therapeutics
- Screening compounds targeting IL-17/IL-23 and related inflammatory pathways
- Investigation of innate and adaptive immune mechanisms in PsA
- Preclinical efficacy studies for biologics and small molecules
- Extensive experience in inflammatory and autoimmune disease models
- Proven expertise in establishing reproducible PsA mouse models
- Flexible study design tailored to client-specific research goals
- Comprehensive data outputs, including clinical, histological, and molecular endpoints
- High-quality, reliable results to support preclinical decision-making and accelerate drug development
